Taiwan Stock Exchange · Healthcare
Lotus Pharmaceutical stock from India: price, numbers and tax
Lotus Pharmaceutical (1795) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Lotus Pharmaceutical at a glance
- Price
- NT$177.50-NT$1.50 (0.84%)
- Market cap
- NT$46.65B
- Day range
- NT$177.00 – NT$180.00
- P/E
- 12.28
- Dividend yield
- 1.45%
- Volume
- 228.93K
- 1 month
- -4.57%
- 6 months
- -14.25%
- YTD
- -37.28%
- 1 year
- -31.60%
- 5 years
- +70.67%
Lotus Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$20.5B | NT$18.6B | NT$17.0B | NT$14.6B | NT$12.6B |
| Gross profit | NT$10.6B | NT$10.9B | NT$9.4B | NT$7.8B | NT$5.6B |
| Operating income | NT$5.9B | NT$6.0B | NT$4.9B | NT$4.3B | NT$2.2B |
| Net income | NT$4.7B | NT$5.1B | NT$4.1B | NT$3.0B | NT$1.4B |
| Earnings per share | NT$18.14 | NT$19.35 | NT$15.72 | NT$11.59 | NT$5.50 |
| EBITDA | NT$7.4B | NT$8.2B | NT$6.9B | NT$5.3B | NT$2.9B |
| Total assets | NT$106.2B | NT$40.1B | NT$33.0B | NT$29.5B | NT$21.2B |
| Total debt | NT$55.9B | NT$13.7B | NT$11.6B | NT$8.9B | NT$6.4B |
| Cash and short-term investments | NT$7.7B | NT$6.0B | NT$1.8B | NT$2.0B | NT$1.6B |
| Shareholders' equity | NT$23.8B | NT$21.2B | NT$17.3B | NT$13.9B | NT$11.1B |
| Operating cash flow | NT$7.5B | NT$6.2B | NT$1.6B | NT$3.7B | NT$119.7M |
| Free cash flow | NT$3.1B | NT$4.7B | −NT$1.7B | NT$650.0M | −NT$1.5B |
| Capital expenditure | −NT$4.4B | −NT$1.5B | −NT$3.3B | −NT$577.2M | −NT$1.6B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Bora Pharmaceuticals | 6472.TW | NT$431.00 | NT$54.90B |
| Handa Pharmaceuticals | 6620.TWO | $147.00 | $24.48B |
| TTY Biopharm | 4105.TWO | $78.30 | $19.47B |
| Synmosa Biopharma | 4114.TWO | $29.45 | $15.89B |
| YungShin Global | 3705.TW | NT$56.20 | NT$14.97B |
| Grape King Bio | 1707.TW | NT$85.40 | NT$12.65B |
| Standard Chem & Pharm | 1720.TW | NT$55.90 | NT$10.99B |
| SCI Pharmtech | 4119.TW | NT$55.30 | NT$6.61B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Lotus Pharmaceutical from India
What Lotus Pharmaceutical does
Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. Lotus Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Lotus Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.